Douglas Miller, Ph.D., Managing Director, BioProcess Technology Group, BDO has 30 years of experience in Process and Product Development in the biotechnology industry. His experience includes both upstream and downstream process development of protein therapeutics, cell and gene therapy process development, process scale-up and technology transfer, scientific project team leadership, pilot plant operations management, manufacturing technology development, and plant-to-plant operational alignment and governance. His current activities include development and implementation of CMC strategies, CDMO selection and management, process and product development for cell and gene therapy and monoclonal antibody products, and CMC due diligence.
Prior to joining BDO, Dr. Miller served as Head of Process Development and Platform Strategy at Juno Therapeutics where he was responsible for process development activities for CARs and TCRs and lentiviral vectors, as well as for development of platform technologies to enable best-in-class manufacturing processes for autologous T-cell therapies. Dr. Miller held roles of increasing responsibility at Immunex and Amgen for 20 years, including cell culture process development and scale-up, technology transfer, GMP manufacturing technical support, and pilot plant leadership, culminating in the position of Executive Director, Process and Product Development. He contributed to the development of over 25 monoclonal antibodies/recombinant proteins, and he played a significant role in the development and implementation of single-use bioreactors and technologies for the Manufacturing of the Future platform at Amgen.
Dr. Miller earned his B.S. in Chemical Engineering from Colorado State University and his Ph.D. in Chemical Engineering from the University of California at Berkeley.